Kymriah

November 8, 2017

Novartis Files for Approval of Kymriah for Two Blood Cancers in the EU

News

Novartis continues the process of making Kymriah (tisagenlecleucel) commercially available outside the U.S., now by applying with the European Medicines Agency (EMA) to approve the treatment for two types of ... Read more

November 2, 2017

Novartis Asks FDA to Approve Kymriah for Difficult-to-treat DLBCL

News

Novartis has asked U.S. regulators to expand their approval of Kymriah (tisagenlecleucel) to include the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL. The Food ... Read more

August 31, 2017September 1, 2017

FDA Approves First-Ever CAR T-Cell Therapy, Kymriah, for Young B-Cell ALL Patients

News

In what is described as a historical decision, the U.S. Food and Drug Administration (FDA) has approved the first gene therapy-based cancer treatment in the United States. The FDA approved Novartis’ ... Read more